Discover
ACRS
Aclaris Therapeutics, Inc.
5.34
2 x 4.03
2 x 6.74
bid
ask
+
0.05
0.95%
2 @ 05:58 AM
5.24 -0.10 (1.87%)
| Ytd | 77.41% | |
| 1y | 278.72% |
5.24
day range
5.69
1.39
52 week range
5.69
| Open | 5.59 | Prev Close | 5.29 | Low | 5.24 | High | 5.69 | Mkt Cap | 745.80M |
| Vol | 2.39M | Avg Vol | 1.53M | EPS | -0.56 | P/E | N/A | Forward P/E | -5.00 |
| Beta | 0.12 | Short Ratio | 0.47 | Inst. Own | 90.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.59 | 200-d Avg | 3.36 | 1yr Est | 10.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -0.08 | -0.11 | -0.03 | -37.50% |
| 2024-08-07 | 2024-06 | -0.19 | -0.15 | 0.04 | 21.05% |
| 2024-05-07 | 2024-03 | -0.28 | -0.24 | 0.04 | 14.29% |
| 2024-02-27 | 2023-12 | -0.37 | -0.3 | 0.07 | 18.92% |
| 2023-11-06 | 2023-09 | -0.48 | -0.41 | 0.07 | 14.58% |
| 2023-08-07 | 2023-06 | -0.45 | -0.42 | 0.03 | 6.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-23 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| 2024-11-19 | Leerink Partners | Upgrade | Market Perform | Outperform |
| 2024-11-19 | Jefferies | Upgrade | Hold | Buy |
| 2024-11-19 | BTIG | Upgrade | Neutral | Buy |
| 2024-11-18 | Piper Sandler | Upgrade | Neutral | Overweight |
| 2024-09-17 | HC Wainwright & Co. | Upgrade | Neutral |
Profile
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-29 | BALTHASER KEVIN J | Chief Financial Officer | 24.70K | Conversion of Exercise of derivative security |
| 2024-05-30 | HUMPHRIES WILLIAM DOUGLAS | Director | 28.73K | Conversion of Exercise of derivative security |
| 2024-08-04 | LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-11-18 | MEHRA ANAND | Director | 710.03K | Purchase |
| 2024-05-30 | MILANO VINCENT J | Director | 12.52K | Conversion of Exercise of derivative security |
| 2024-05-30 | MOLINEAUX CHRISTOPHER P | Director | 53.16K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BML Capital Management, LLC | 14.25M | 41.33M | 13.32% |
| 2024-09-29 | Vanguard Group Inc | 4.69M | 13.59M | 4.38% |
| 2024-09-29 | Shaw D.E. & Co., Inc. | 3.37M | 9.78M | 3.15% |
| 2024-09-29 | Millennium Management Llc | 3.01M | 8.72M | 2.81% |
| 2024-09-29 | Rock Springs Capital Management, LP | 2.75M | 7.99M | 2.57% |
| 2024-09-29 | Stonepine Capital Management, LLC | 2.46M | 7.13M | 2.30% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.12M | 6.13M | 1.98% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 820.73K | 2.38M | 0.77% |
| 2024-09-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 706.50K | 2.05M | 0.66% |
| 2024-09-29 | Vanguard Variable Insurance Fund-Small Company Growth | 639.02K | 1.85M | 0.60% |
| 2024-10-30 | iShares Biotechnology ETF | 491.47K | 1.43M | 0.46% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 403.79K | 1.17M | 0.38% |